Research Article - Journal of RNA and Genomics (2022) Volume 0, Issue 0

Clinical study evaluating ?-blockers use and fracture risk in patients with primary osteoporosis

Introduction: Osteoporosis is a disease identified by low bone mass, in parallel with an intensification of bone fragility. Several observational studies suggested that users of beta-blockers (BB) had higher bone mineral density (BMD) and/or reduced fracture risk. Other studies, on the other hand, found no effect of BB on fracture risk or improving osteoporosis disease state. Objective: To investigate the relationship between the use of selective and non-selective BB and fracture risk in male and female osteoporotic patients. Methods: This is a randomized, controlled, parallel, prospective study that involves fifty osteoporotic patients of both sexes with osteoporosis. These osteoporotic patients are treated with (osteoporosis standard therapy) and were divided into three groups: control group (CG) contained 10 patients, nonselective beta-blocker group (NSBB), and cardio-selective beta-blocker group (CSBB) each BB group containing 20 patients. Then, the effect of BB on T-score, bone mineral density (BMD), fracture risk (FR), and bone turnover markers were studied. Results: A significant difference was noticed between mean values of T-score among the three studied groups after six months of follow-up. BMD was statistically significantly higher in (NSBB & CSBB) groups compared to the CG group. The fracture risk was statistically significantly lower in both (NSBB & CSBB) groups in the three types of fracture risk region. Moreover, there was a drop in bone turnover markers (BTM) in both groups (NSBB or CSBB) compared to the control group. Conclusion: The usage of BB either (NSBB or CSBB) improves osteoporosis disease state by increasing BMD, lowering FR, and decrease BTM.

Author(s): Mona Abd Elrafea Abdo*, Osama Mohamed Ibrahim, Sahar Mohamed El-Hagga, Salwa Elmorsy El-Sayed

Abstract PDF